Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

T-cell engaging bispecific antibody shows potent MRD negativity with variable remission and survival outcomes: A bayesian meta-analysis of randomized controlled trials

View Full Paper
Ask AI
Bookmark
Share

Authors

HSHeer ShahKKKrish Keswani

Discussion

Loading...

Member takes

Overview

Bayesian meta-analysis of randomized controlled trials shows blinatumomab enhances MRD negativity in B-ALL, suggesting improved outcomes.

Key Points

  • Blinatumomab improves measurable residual disease (MRD) negativity, aiding in potential curative therapies.
  • Pooled results of randomized controlled trials indicate efficacy in achieving MRD negativity with varying remission rates.
  • The use of a Bayesian model allows for assessment of treatment heterogeneity across multiple trial designs and patient populations.
  • Further investigation is warranted in high-risk cohorts to optimize use of blinatumomab in B-ALL treatment.

Cite This Study

Shah et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e515https://doi.org/10.1182/blood-2025-6868
View Full Paper
Ask AI
Bookmark
Share